Germline variants associated with toxicity to immune checkpoint blockade

Stefan Groha(Dana-Farber Cancer Institute), Alexander Gusev(Dana-Farber Cancer Institute), Tanya E. Keenan(Massachusetts General Hospital), Leyre Zubiri(Massachusetts General Hospital), Talal El Zarif(Yale University), Ziad Bakouny(Dana-Farber Cancer Institute), Biagio Ricciuti(Harvard University), Christian Hammer(SIB Swiss Institute of Bioinformatics), Kerry L. Reynolds(Massachusetts General Hospital), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Alexandra–Chloé Villani(Broad Institute), Renée Maria Saliby(Yale University), Toni K. Choueiri(Harvard University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Yevgeniy R. Semenov(Harvard University), Kenneth L. Kehl(Dana-Farber Cancer Institute), Wenxin Xu(Dana-Farber Cancer Institute), Elio Adib(Dana-Farber Brigham Cancer Center), David A. Braun(Yale Cancer Center), Michael P. Manos(Harvard University), Guihong Wan(Harvard University), Ahmad Rajeh(Massachusetts General Hospital), Amin H. Nassar(Brigham and Women's Hospital), Vivek Naranbhai(Centre for Human Genetics), Osama E. Rahma(Dana-Farber/Harvard Cancer Center), Sachet A. Shukla(Broad Institute), Joao V. Alessi(Hospital Sírio-Libanês), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Matthew L. Freedman(Brigham and Women's Hospital), Andrew Schmidt(Dana-Farber Cancer Institute), Deborah Schrag(Dana-Farber Brigham Cancer Center), Zia Khan, Sarah Abou Alaiwi(Yale New Haven Hospital), Benjamin P. Fairfax(University of Oxford), Chris Labaki(Beth Israel Deaconess Medical Center)
Nature Medicine
December 1, 2022
Cited by 106


Related Papers